New Ray Medicine International Holding (HKG:6108) recorded a loss attributable to owners of HK$4.09 million for the six months ended June 30, narrower than HK$13.4 million logged for the corresponding period last year, a Tuesday filing with the Hong Kong Exchange said.
Loss per share stood at HK$0.0024 for the reporting period, compared to HK$0.0080 recorded for the year-ago period.
The investment and pharmaceutical company's revenue for the first half of this year was HK$16.7 million, 46.1% lower than HK$31.0 million booked a year ago. The company attributed the decrease in revenue to a decrease in demand for its products in the market.